Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)’s share price gapped up prior to trading on Friday . The stock had previously closed at $117.16, but opened at $123.66. Alnylam Pharmaceuticals shares last traded at $125.59, with a volume of 2613370 shares.

A number of equities analysts have weighed in on ALNY shares. Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $62.00 to $163.00 in a research note on Monday, October 2nd. Jefferies Group set a $102.00 price target on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 25th. B. Riley lowered their price target on shares of Alnylam Pharmaceuticals to $220.00 and set a “buy” rating for the company in a research report on Wednesday, November 8th. BMO Capital Markets reiterated an “outperform” rating and set a $99.00 price target (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 6th. Finally, Leerink Swann reiterated a “market perform” rating and set a $72.00 price target (down previously from $83.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, September 8th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Buy” and a consensus price target of $121.85.

The company has a quick ratio of 9.83, a current ratio of 9.83 and a debt-to-equity ratio of 0.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). The company had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. Alnylam Pharmaceuticals’s revenue for the quarter was up 24.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.21) earnings per share. analysts expect that Alnylam Pharmaceuticals, Inc. will post -5.21 earnings per share for the current year.

In related news, Director Dennis A. Ausiello sold 20,000 shares of the company’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $130.00, for a total value of $2,600,000.00. Following the transaction, the director now directly owns 20,000 shares in the company, valued at $2,600,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO John Maraganore sold 74,000 shares of the company’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $126.86, for a total transaction of $9,387,640.00. Following the completion of the transaction, the chief executive officer now owns 223,710 shares in the company, valued at $28,379,850.60. The disclosure for this sale can be found here. Insiders sold 393,212 shares of company stock worth $48,109,436 over the last three months. Insiders own 4.30% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. Public Employees Retirement System of Ohio grew its stake in Alnylam Pharmaceuticals by 3.2% during the third quarter. Public Employees Retirement System of Ohio now owns 32,880 shares of the biopharmaceutical company’s stock worth $3,863,000 after buying an additional 1,026 shares in the last quarter. Security National Bank of SO Dak acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth about $247,000. California Public Employees Retirement System grew its stake in Alnylam Pharmaceuticals by 5.1% during the third quarter. California Public Employees Retirement System now owns 133,206 shares of the biopharmaceutical company’s stock worth $15,650,000 after buying an additional 6,506 shares in the last quarter. Virtu Financial LLC acquired a new stake in Alnylam Pharmaceuticals during the third quarter worth about $286,000. Finally, Orbimed Advisors LLC grew its stake in Alnylam Pharmaceuticals by 69.7% during the third quarter. Orbimed Advisors LLC now owns 1,084,800 shares of the biopharmaceutical company’s stock worth $127,453,000 after buying an additional 445,600 shares in the last quarter. Hedge funds and other institutional investors own 88.43% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/alnylam-pharmaceuticals-alny-shares-gap-up-to-123-66/1769950.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.